title: Characterization of the beta 1-adrenoceptor stimulatory effects of the partial beta 1-agonists acebutolol, xamoterol, H142/08 and H201/70.
abstract: The beta 1-adrenoceptor stimulatory effects of the partial beta 1-agonists acebutolol, xamoterol, H142/08 and H201/70 were investigated in the isolated right atrium (frequency response) of the rat. All the partial agonists studied induced a concentration-dependent increase in atrial rate. This effect was antagonized by the beta 1-selective blocker pafenolol. The concentrations of H142/08 and H201/70 needed to produce a half maximal response (-log EC50: pD2) were significantly greater than those required to occupy half the receptor population (-log equilibrium dissociation constant: pKB). These compounds required a fractional receptor occupancy of 80-90% to produce half the maximal stimulatory effect while the corresponding receptor occupancy for the other partial agonists studied was about 20%. The maximal stimulatory effect (intrinsic activity) generated by the compounds in the right atrium was (mean +/- S.D.): xamoterol 60 +/- 11%, H142/08 30 +/- 9%, H201/70 18 +/- 3% and acebutolol 17 +/- 8%. In addition, the stimulatory potency of the partial agonists was calculated as the efficacy (e) of the compounds relative to that of isoprenaline. The relative efficacy, expressed as -log[e(partial agonist/e(isoprenaline)] was: xamoterol 2.2 +/- 0.4, acebutolol 3.0 +/- 0.2, H142/08 3.4 +/- 0.2 and H201/70 3.6 +/- 0.2. It is concluded that partial beta 1-agonists have different relationships between their stimulatory effect and fractional receptor occupancy. There was a poor correlation between the intrinsic activity and relative efficacy of partial beta 1-agonists in the right atrium.
authors.affiliation: Department of Pharmacology, Hässle Cardiovascular Research Laboratories, Mölndal, Sweden.
authors.forename: T
authors.initials: T
authors.lastname: Abrahamsson
mesh_terms: D000070:Acebutolol / Q000494:pharmacology*; D000318:Adrenergic beta-Agonists / Q000494:pharmacology; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology*; D000818:Animals; D005260:Female; D006321:Heart / Q000187:drug effects; D006339:Heart Rate / Q000187:drug effects; D066298:In Vitro Techniques; D007545:Isoproterenol / Q000494:pharmacology; D008297:Male; D011412:Propanolamines / Q000494:pharmacology*; D051381:Rats; D014590:Uterine Contraction / Q000187:drug effects; D017307:Xamoterol; D000092502:Renin Inhibitors
chemical_list: D000070:Acebutolol; D000318:Adrenergic beta-Agonists; D000319:Adrenergic beta-Antagonists; D007545:Isoproterenol; D011412:Propanolamines; D017307:Xamoterol; D000092502:Renin Inhibitors; C060565:H 201-70; C060566:H 142-08